ReferenceCitation: Miere A, Capuano V, Kessler A, Zambrowski O, Jung C, Colantuono D, Pallone C, Semoun O, Petit E, Souied E. Deep learning-based classification of retinal atrophy using fundus autofluorescence imaging. Comput Biol Med. 2021 Mar;130:104198. doi: 10.1016/j.compbiomed.2020.104198. Epub 2020 Dec 28.

family: Miere

full_name: Alexandra Miere

given: Alexandra

family: Capuano

full_name: Vittorio Capuano

given: Vittorio

family: Kessler

full_name: Arthur Kessler

given: Arthur

family: Zambrowski

full_name: Olivia Zambrowski

given: Olivia

family: Jung

full_name: Camille Jung

given: Camille

family: Colantuono

full_name: Donato Colantuono

given: Donato

family: Pallone

full_name: Carlotta Pallone

given: Carlotta

family: Semoun

full_name: Oudy Semoun

given: Oudy

family: Petit

full_name: Eric Petit

given: Eric

family: Souied

full_name: Eric Souied

journal_name: Computers in Biology and Medicine

family: Heier

full_name: Jeffrey S. Heier

given: Jeffrey S.

family: Pieramici

full_name: Dante Pieramici

given: Dante

family: Chakravarthy

full_name: Usha Chakravarthy

given: Usha

family: Patel

full_name: Sunil S. Patel

given: Sunil S.

family: Gupta

full_name: Sunil Gupta

title: Visual Function Decline Resulting from Geographic Atrophy

title: Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration

location_country:
Italy
Austria
Peru
Switzerland
Mexico
Netherlands
Germany
France
Poland
Slovakia
Hungary
Argentina
Australia
Belgium
Spain
Denmark
United States
United Kingdom
Canada

location_facility: Hospital Universitario Rio Hortega; Servicio de Oftalmologia

location_facility: Instituto Clinico Quirurgico de Oftalmologia - ICQO

location_facility: Northwestern Medical Group/Northwestern University

location_facility: Universitätskliniikum Schleswig-Holstein, Campus Lübeck, Klinik für Augenheilkunde

location_facility: Kepler Universitätskliniken GmbH - Med Campus III; Abt. für Augenheilkunde

location_facility: FISABIO. Fundación Oftalmologica del Mediterraneo

location_facility: Hospital Universitari de Bellvitge; Servicio de Oftalmologia

location_facility: SP ZOZ Szpital Uniwersytecki w Krakowie Oddział Kliniczny Okulistyki i Onkologii Okulistycznej

location_facility: Cleveland Clinic Foundation; Cole Eye Institute

location_facility: CHU Poitiers - CHR La Miletrie; Ophtalmologie

location_facility: The Gavin Herbert Eye Institute - UC, Irvine

location_facility: VISSUM Instituto Oftalmológico de Alicante

location_facility: CLINICA RICARDO PALMA; Oftalmologos Contreras

location_facility: Fakultna nemocnica s poliklinikou Zilina; Ocne oddelenie

location_facility: Uni of Alabama At Birmingham Clinical Research Unit

location_facility: Fondazione Irccs Ca' Granda Ospedale Maggiore Policlinico-Clinica Regina Elena;U.O.C Oculistica

location_facility: Centre Ophtalmologique; Imagerie et laser

location_facility: Debreceni Egyetem Klinikai Kozpont; Szemeszeti Klinika

location_facility: Retina-Vitreous Associates Medical Group

location_facility: Eye Surgeons of Richmond Inc. dba Virginia Eye Institute

location_facility: Augenabteilung am St. Franziskus-Hospital

location_facility: Azienda Ospedaliero Universitaria Di Sassari;U.O. Oculistica

location_facility: University Health Network Toronto Western Hospital

location_facility: Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Augenheilkunde

location_facility: Centre Odeon; Exploration Ophtalmologique

location_facility: Fondazione Ptv Policlinico Tor Vergata Di Roma;U.O.S.D. Patologie Renitiche

location_facility: Sjællands Universitetshospital, Roskilde; Øjenafdelingen

location_facility: Gabinet Okulistyczny Prof Edward Wylegala

location_facility: Medizinische Hochschule Hannover, Klinik für Augenheilkunde

location_facility: Academisch Medisch Centrum Universiteit Amsterdam

location_facility: University Retina and Macula Associates, PC

location_facility: Fondazione G.B. Bietti Per Lo Studio E La Ricerca in Oftalmologia-Presidio Ospedaliero Britannico


title: An Open, Randomized, Multicenter, Phase IIIB Study During 5 Years to Assess Long-term Efficacy and Tolerability of Esomeprazole Compared to Laparoscopic Anti-reflux Surgery in Adult Subjects With Gastroesophageal Reflux Disease - LOTUS.

acronym: LOTUS

summary: The study investigates the efficacy of long-term treatment of esomeprazole compared to anti-reflux surgery in the control of gastroesophageal reflux disease by assessing time to treatment failure.

status: Completed

study_completion_date_type: Actual

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Actual

ReferenceType: derived

ReferenceCitation: Hatlebakk JG, Zerbib F, Bruley des Varannes S, Attwood SE, Ell C, Fiocca R, Galmiche JP, Eklund S, Långström G, Lind T, Lundell LR; LOTUS Study Group. Gastroesophageal Acid Reflux Control 5 Years After Antireflux Surgery, Compared With Long-term Esomeprazole Therapy. Clin Gastroenterol Hepatol. 2016 May;14(5):678-85.e3. doi: 10.1016/j.cgh.2015.07.025. Epub 2015 Jul 27.

family: Hatlebakk

full_name: Jan G. Hatlebakk

given: Jan G.

sequence: first

family: Zerbib

full_name: Frank Zerbib

given: Frank

sequence: additional

family: Bruley des Varannes

full_name: Stanislas Bruley des Varannes

given: Stanislas

family: Attwood

full_name: Stephen E. Attwood

given: Stephen E.

family: Ell

full_name: Christian Ell

given: Christian

family: Fiocca

full_name: Roberto Fiocca

given: Roberto

family: Galmiche

full_name: Jean-Paul Galmiche

given: Jean-Paul

family: Eklund

full_name: Stefan Eklund

given: Stefan

family: Långström

full_name: Göran Långström

given: Göran

family: Lind

full_name: Tore Lind

given: Tore

family: Lundell

full_name: Lars R. Lundell

given: Lars R.

bso_classification: Medical research

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Clinical Gastroenterology and Hepatology

oa_host_type: publisher

evidence: open (via free pdf)

host_type: publisher

license_normalized: no license

version: publishedVersion

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

ReferenceCitation: Attwood SE, Ell C, Galmiche JP, Fiocca R, Hatlebakk JG, Hasselgren B, Långström G, Jahreskog M, Eklund S, Lind T, Lundell L. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015 Jun;41(11):1162-74. doi: 10.1111/apt.13194. Epub 2015 Apr 10.

name: North Tyneside General Hospital; North Shields UK

full_name: S. E. Attwood

given: S. E.

name: Sana Klinikum Offenbach; Frankfurt Germany

full_name: C. Ell

given: C.

full_name: J. P. Galmiche

given: J. P.

name: University of Genoa and IRCCS S. Martino; Genoa Italy

full_name: R. Fiocca

given: R.

name: Haukeland University Hospital; Bergen Norway

full_name: J. G. Hatlebakk

given: J. G.

family: Hasselgren

full_name: B. Hasselgren

given: B.

full_name: G. Långström

given: G.

family: Jahreskog

full_name: M. Jahreskog

given: M.

full_name: S. Eklund

name: Department of Surgery; Centre for Digestive Diseases; Karolinska University Hospital; CLINTEC; Karolinska Institutet; Stockholm Sweden

ReferenceCitation: Lundell L, Hatlebakk J, Galmiche JP, Attwood SE, Ell C, Fiocca R, Persson T, Nagy P, Eklund S, Lind T. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial. Curr Med Res Opin. 2015 Jan;31(1):65-73. doi: 10.1185/03007995.2014.980500. Epub 2014 Oct 31.

name: aDepartment of Surgery, Centre for Digestive Diseases, Karolinska University Hospital, CLINTEC, Karolinska Institutet, Stockholm, Sweden

name: bDepartment of Medicine, Haukeland University Hospital, Bergen, Norway

name: cHôtel Dieu-CHU University de Nantes, Nantes, France

name: dNorth Tyneside Hospital, North Shields, UK

name: eSana Klinikum Offenbach, Teaching Hospital of the Goethe University Frankfurt, Frankfurt, Germany

name: fUniversity of Genoa and IRCCS S. Martino/IST, Genoa, Italy

ReferenceCitation: Fiocca R, Mastracci L, Attwood SE, Ell C, Galmiche JP, Hatlebakk J, Bärthel A, Långström G, Lind T, Lundell L; LOTUS trial collaborators. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012 Nov;36(10):959-71. doi: 10.1111/apt.12052. Epub 2012 Sep 23.

name: Department of Surgical and Morphological Sciences; University of Genoa; Genoa; Italy

name: North Tyneside Hospital; North Shields; UK

name: Dr.-Horst-Schmidt-Kliniken Wiesbaden; Wiesbaden; Germany

name: Hotel Dieu-CHU de Nantes; Nantes; France

name: Haukeland University Hospital; Bergen; Norway

name: Karolinska University Hospital Huddinge; Stockholm; Sweden

ReferenceCitation: Galmiche JP, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Långström G, Lind T, Lundell L; LOTUS Trial Collaborators. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. 2011 May 18;305(19):1969-77. doi: 10.1001/jama.2011.626.

title: Laparoscopic Antireflux Surgery vs Esomeprazole Treatment for Chronic GERD

location_country:
Italy
Austria
Sweden
Netherlands
Finland
France
Norway
Belgium
Denmark
Germany
United Kingdom
Iceland


title: Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/Ritonavir Compared to Open-label Current PI Therapy in HIV-1 Infected, Protease Inhibitor Experienced Adults for 2 Weeks With Long-term Assessment (>48 Weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen

summary: This is a two phase study (randomised and non-randomised phase). The randomised phase will initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current background therapy) in comparison to an ongoing, open-labeled rtv-boosted protease inhibitor (PI) regimen for 15 days. At the Day 15 visit, all subjects will optimize background therapy. Additionally, subjects receiving the lowest dose of GW640385 will be re-randomised to one of the higher doses and subjects in the control arm will receive a new rtv-boosted PI based on resistance testing at screening. Subjects will remain in the randomized phase on one of these 4 continuing treatment arms for at least 48 weeks. An interim analysis will occur during the randomised phase to select for a dose of GW640385 to evaluate further in Phase III studies. After dose selection subjects will move to the non-randomised phase of the study. In the non-randomised phase subjects who are receiving GW640385 will be assigned to final selected dose for assessment of long term safety, tolerability, pharmacokinetics, and antiviral activity.

status: Terminated

lead_sponsor: ViiV Healthcare

location_country:
Italy
United States
Germany
France
Romania
Belgium
Australia
Puerto Rico
Portugal
Canada
United Kingdom

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Unknown


title: A Multicentre Prospective Controlled Observer Blinded Cohort Study in Patients With Acromegaly to Evaluate the Risk of Cardiac Valvular Regurgitation in Patients Treated With Lanreotide Relative to Patients Treated With Octreotide

summary: The aim of the study is to compare the risk of acromegaly patients developing valvular regurgitation when receiving lanreotide or octreotide

study_type: Observational

time_perspective: Prospective

ReferenceType: result

ReferenceCitation: Colao A, Marek J, Goth MI, Caron P, Kuhn JM, Minuto FM, Weissman NJ. No greater incidence or worsening of cardiac valve regurgitation with somatostatin analog treatment of acromegaly. J Clin Endocrinol Metab. 2008 Jun;93(6):2243-8. doi: 10.1210/jc.2007-2199. Epub 2008 Apr 1.

name: Department of Molecular and Clinical Endocrinology and Oncology (A.C.), Charles University, Prague 12108, Czech Republic

family: Colao

full_name: Annamaria Colao

given: Annamaria

name: Department of Federico II University of Naples, 80131 Naples, Italy; 1st School of Medicine (J.M.), Charles University, Prague 12108, Czech Republic

family: Marek

full_name: Josef Marek

given: Josef

name: Division of Endocrinology (M.I.G.), Department of Medicine, National Medical Center, Budapest 1135, Hungary

family: Goth

full_name: Miklos I. Goth

given: Miklos I.

name: Department of Endocrinology and Metabolic Diseases (P.C.), Centre Hospitalier Universitaire Larrey, Toulouse 31059, France

family: Caron

full_name: Philippe Caron

given: Philippe

name: Institut National de la Santé et de la Recherche Médicale 0204 (J.M.K.), Hôpital Centre d’Investigation Clinique, Charles Nicolle, Rouen 76031, France

family: Kuhn

full_name: Jean Marc Kuhn

given: Jean Marc

name: Department of Endocrinology and Metabolism (F.M.M.), University of Genova, 16132 Genova, Italy

family: Minuto

full_name: Francesco M. Minuto

given: Francesco M.

name: Department of Cardiovascular Research Institute/Washington Hospital Center (N.J.W.), Washington, DC 20010

family: Weissman

full_name: Neil J. Weissman

given: Neil J.

journal_name: The Journal of Clinical Endocrinology & Metabolism

publisher: The Endocrine Society

publisher_dissemination: The Endocrine Society

publisher_group: The Endocrine Society

publisher_normalized: The Endocrine Society

title: No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly

lead_sponsor: Ipsen

location_country:
Italy
Sweden
France
Czechia
Poland
Hungary
Belgium
Spain
Denmark
United Kingdom

location_facility: Dipartimento di Scienze, Endocrinologiche e Metaboliche

location_facility: Research Centre for Endocrinology and Metabolism

location_facility: 1st School of Medicine, Charles University

status_simplified: Completed


type: EudraCT Number

type: Other Identifier

title: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Investigate the Efficacy and Tolerability of Topiramate in Prolonged Migraine Prevention

acronym: PROMPT

summary: The purpose of this study is to evaluate the safety and effectiveness (beyond 6 months) of individualized doses (100 to 200 milligrams) of topiramate for the prevention of migraine headaches over a period of 26 weeks.

ReferenceCitation: Diener HC, Agosti R, Allais G, Bergmans P, Bussone G, Davies B, Ertas M, Lanteri-Minet M, Reuter U, Sánchez Del Río M, Schoenen J, Schwalen S, van Oene J; TOPMAT-MIG-303 Investigators Group. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2007 Dec;6(12):1054-62. Epub 2007 Nov 7. Erratum in: Lancet Neurol. 2008 Jan;7(1):25.

lead_sponsor: Janssen Pharmaceutica N.V., Belgium

location_country:
Austria
Saudi Arabia
Switzerland
Spain
United Kingdom
France
Bulgaria
Greece
Poland
Slovenia
Norway
Hungary
Belgium
Ireland
Russian Federation
Portugal
Turkey
Denmark
Germany
Czech Republic


title: A Ten-Week, Randomized, Double-Blind Study Evaluating the Efficacy of Duloxetine 60mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain

summary: To determine the efficacy of Duloxetine vs. placebo on pain as determined by change in the Brief Pain Inventory (BPI) from baseline over 8 weeks of treatment

ReferenceCitation: Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S. Time course of improvement of different symptom clusters in patients with major depression and pain treated with duloxetine or placebo. Curr Med Res Opin. 2012 Jan;28(1):41-8. doi: 10.1185/03007995.2011.645561. Epub 2011 Dec 22.

name:
University Psychiatric Center KuLeuven, Campus Gasthuisberg
Leuven Belgium

family: Demyttenaere

full_name: Koen Demyttenaere

given: Koen

name:
Lilly Research Laboratories, Eli Lilly and Company
Indianapolis, INUSA

family: Desaiah

full_name: Durisala Desaiah

given: Durisala

name:
Boehringer Ingelheim Pharmaceuticals Inc.
Ridgefield, CT USA

family: Petit

full_name: Claude Petit

given: Claude

name: Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach Germany

family: Croenlein

full_name: Jens Croenlein

given: Jens

name:
Boehringer Ingelheim GmbH
Ingelheim Germany

family: Brecht

full_name: Stephan Brecht

given: Stephan

journal_name: Current Medical Research and Opinion

publisher: Informa Healthcare

publisher_dissemination: Informa

publisher_group: Informa

publisher_normalized: Informa

ReferenceCitation: Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S. Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2009;11(1):8-15.

ReferenceCitation: Brecht S, Courtecuisse C, Debieuvre C, Croenlein J, Desaiah D, Raskin J, Petit C, Demyttenaere K. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. J Clin Psychiatry. 2007 Nov;68(11):1707-16.

lead_sponsor: Eli Lilly and Company

location_country:
Finland
France
Slovakia
Belgium
Germany
Czech Republic

location_facility: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.


title: PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis

summary: The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor, Samertan, Telmisartan] is superior to placebo, in the presence of background antihypertensive therapy, in prevention of a second stroke in patients who have recently suffered a stroke and therefore are at high risk of suffering another one.

primary_purpose: Prevention

ReferenceCitation: Ovbiagele B, Bath PM, Cotton D, Sha N, Diener HC; PRoFESS Investigators. Low glomerular filtration rate, recurrent stroke risk, and effect of renin-angiotensin system modulation. Stroke. 2013 Nov;44(11):3223-5. doi: 10.1161/STROKEAHA.113.002463. Epub 2013 Aug 29.

name: From the Department of Neurosciences, Medical University of South Carolina, Charleston, SC (B.O.); Stroke Trials Unit, University of Nottingham, United Kingdom (P.M.B.); Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT (D.C., N.S.); and Department of Neurology, University of Duisburg-Essen, Essen, Germany (H.-C.D.).

family: Ovbiagele

full_name: Bruce Ovbiagele

given: Bruce

family: Bath

full_name: Philip M. Bath

given: Philip M.

family: Cotton

full_name: Daniel Cotton

given: Daniel

family: Sha

full_name: Nanshi Sha

given: Nanshi

family: Diener

full_name: Hans-Christoph Diener

given: Hans-Christoph

journal_name: Stroke

oa_colors: green hybrid

oa_host_type: publisher;repository

evidence: oa repository (via OAI-PMH doi match)

host_type: repository

repository_institution: PubMed Central - Europe PMC

repository_normalized: PubMed Central

version: acceptedVersion

evidence: oa repository (via pmcid lookup)

publisher: Ovid Technologies (Wolters Kluwer Health)

publisher_dissemination: Wolters Kluwer Health

publisher_group: Wolters Kluwer Health

publisher_normalized: Wolters Kluwer Health

title: Low Glomerular Filtration Rate, Recurrent Stroke Risk, and Effect of Renin–Angiotensin System Modulation

ReferenceCitation: Böhm M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R, Bath PM, Yusuf S, Diener HC. Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. Eur Heart J. 2012 Nov;33(22):2804-12. doi: 10.1093/eurheartj/ehs250. Epub 2012 Aug 26.

family: Bohm

full_name: M. Bohm

full_name: D. Cotton

given: D.

family: Foster

full_name: L. Foster

given: L.

family: Custodis

full_name: F. Custodis

given: F.

family: Laufs

full_name: U. Laufs

given: U.

family: Sacco

full_name: R. Sacco

given: R.

full_name: P. M. W. Bath

given: P. M. W.

family: Yusuf

full_name: S. Yusuf

given: S.

full_name: H.-C. Diener

journal_name: European Heart Journal

publisher: Oxford University Press (OUP)

publisher_dissemination: Oxford University Press

publisher_group: Oxford University Press

ReferenceCitation: Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Möller-Hartmann C, Gizewski ER, Forsting M, Demchuk AM, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy. Stroke. 2012 Sep;43(9):2336-42. Epub 2012 Jun 26.

ReferenceCitation: Weber R, Weimar C, Wanke I, Möller-Hartmann C, Gizewski ER, Blatchford J, Hermansson K, Demchuk AM, Forsting M, Sacco RL, Saver JL, Warach S, Diener HC, Diehl A; PRoFESS Imaging Substudy Group. Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy. Stroke. 2012 Feb;43(2):350-5. doi: 10.1161/STROKEAHA.111.631739. Epub 2012 Jan 19.

name: From the Department of Neurology (R.W., C.W., H.C.D.) and Neuroradiology (I.W., C.M.-H., E.R.G., M.F., A.D.), University of Duisburg-Essen, Essen, Germany; Boehringer Ingelheim–Ltd (J.B.), Bracknell, UK; Boehringer Ingelheim AB (K.H.), Stockholm, Sweden; the Departments of Clinical Neurosciences (A.M.D.), Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; the Department of Neurology (R.L.S.), Miller School of Medicine, University of Miami, Miami, FL; the Stroke Center and...

title: Risk of Recurrent Stroke in Patients With Silent Brain Infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Imaging Substudy

ReferenceCitation: Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, Donnan GA, Bath PM; PROFESS Investigators. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011 Nov 16;306(19):2137-44. doi: 10.1001/jama.2011.1650.

title: Level of Systolic Blood Pressure Within the Normal Range and Risk of Recurrent Stroke

ReferenceCitation: Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008 Oct;7(10):875-84. doi: 10.1016/S1474-4422(08)70198-4. Epub 2008 Aug 29. Erratum in: Lancet Neurol. 2008 Nov;7(11):985.

ReferenceCitation: Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37. doi: 10.1056/NEJMoa0804593. Epub 2008 Aug 27.

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - Université de Limoges

repository_institution: University of Nottingham - Repository@Nottingham

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: Seoul National University - Seoul National University Open Repository

repositories_institution: University of Nottingham - Repository@Nottingham

title: Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

ReferenceCitation: Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008 Sep 18;359(12):1238-51. doi: 10.1056/NEJMoa0805002. Epub 2008 Aug 27.

title: Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke

location_country:
Finland
Malaysia
Greece
Australia
Belgium
Russian Federation
Denmark
Taiwan
Ukraine
India
France
Japan
Thailand
Norway
Argentina
El Salvador
Canada
Korea, Republic of
South Africa
Sweden
Hong Kong
Netherlands
Singapore
Ireland
China
Portugal
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Israel
Spain
Turkey

location_facility: 9.159.2101 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1331 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1878 Azienda Ospedaliera "Santo Maria"

location_facility: 9.159.2039 Centro Hospitalar e Universitário de Coimbra, EPE

location_facility: 9.159.2946 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2028 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1151 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1734 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1707 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1736 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2630 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2110 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1728 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1659 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2100 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2609 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2290 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2179 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2284 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2214 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1388 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2213 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1025 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1395 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2511 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2484 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1075 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2951 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2254 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1819 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1871 Azienda Ospedaliera "Careggi"

location_facility: 9.159.2249 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2029 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1083 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1099 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2966 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1729 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1005 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1517 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2631 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1373 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1191 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2933 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1042 Neurology Consultants of Burlington County

location_facility: 9.159.2120 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1721 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2707 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1056 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1063 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1552 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1061 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1201 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1087 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1173 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1369 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1112 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1368 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2094 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1164 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1723 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1081 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1332 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2055 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1875 Università degli Studi di Ancona

location_facility: 9.159.2116 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1824 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1007 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1041 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1023 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1336 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1556 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1714 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1140 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1139 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1597 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1054 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1179 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1633 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1117 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1716 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2447 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1057 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2178 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2515 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2949 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2968 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2388 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2617 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1119 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1188 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2612 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2091 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2215 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1372 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2204 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2109 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2119 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2113 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1118 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2087 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2243 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2181 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1091 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2205 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1145 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2514 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1634 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1366 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1185 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2225 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1355 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1200 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1591 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2384 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1045 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2112 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1181 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1733 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2956 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1551 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2494 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2614 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2613 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1138 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2380 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2104 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1385 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1158 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2935 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2088 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1080 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2080 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1868 Ospedale "S. Maria di Loreto Mare"

location_facility: 9.159.1047 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1092 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1184 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1873 Istituto Scientifico "S. Luca"

location_facility: 9.159.2084 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2942 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2090 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1123 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1334 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2391 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1658 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1046 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1033 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2723 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1393 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2954 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2502 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2493 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2289 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2305 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1142 Saint Luke's-Roosevelt Hospital

location_facility: 9.159.1554 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1717 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2632 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1114 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1104 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2936 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2828 Dkuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D.

location_facility: 9.159.2938 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2446 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1166 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2512 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1596 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2285 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2619 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1012 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2948 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2509 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1681 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1708 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1520 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1727 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1876 Azienda Ospedaliera di Padova -Policlinico Universitario

location_facility: 9.159.1024 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2108 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1085 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1052 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1519 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2245 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1106 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1732 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2206 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1358 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2972 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2294 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1392 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2943 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1715 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2831 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1058 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2098 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2222 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2176 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1006 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1038 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1821 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2705 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1198 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1009 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2083 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1004 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1069 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2506 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1739 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2079 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2450 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2103 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2224 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1718 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2610 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2605 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1037 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1113 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1082 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1074 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1370 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2301 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1135 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1333 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2443 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1020 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1170 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1126 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1096 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1724 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2212 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1390 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2955 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2296 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1711 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1127 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1683 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1022 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1131 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2953 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1108 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1062 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1371 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1036 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2111 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2950 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1010 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1116 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1186 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2703 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1869 Università degli Studi di Genova

location_facility: 9.159.1001 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2616 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2765 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1125 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1640 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2516 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1363 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1059 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1132 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2253 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1212 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1680 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2615 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1365 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1102 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1206 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1391 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1685 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2105 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2211 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1039 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2059 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1072 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2964 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1143 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2713 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2297 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2973 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2623 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1029 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2209 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2386 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1190 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1090 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1335 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1162 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2801 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2626 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1518 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2061 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2714 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2300 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2449 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1389 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1516 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2625 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2216 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1656 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1195 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1710 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1725 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2451 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1086 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2501 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1160 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1378 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1543 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1101 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2097 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2971 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1156 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2830 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2829 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1851 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1174 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2308 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1055 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2624 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2382 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2724 Rambam Medical Center, Tel-Aviv Medical

location_facility: 9.159.2286 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2210 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2203 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2208 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2606 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1638 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1107 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1180 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2392 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1076 North Shore University Hospital

location_facility: 9.159.1655 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1177 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2247 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1088 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1545 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2627 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2379 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2941 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1068 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1594 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2965 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2957 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1216 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1709 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2041 Centro Hospitalar de Lisboa Norte

location_facility: 9.159.1011 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2115 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1211 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2798 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2958 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1379 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1031 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1194 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2505 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1032 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2944 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2106 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2390 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2304 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2497 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2117 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1084 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2498 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1060 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1384 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1077 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1021 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2299 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1381 Ottawa Hospital General Campus

location_facility: 9.159.1147 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1071 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1078 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2827 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1394 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2056 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2496 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1738 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1144 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1684 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2081 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1018 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1205 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1030 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1720 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1165 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1217 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2620 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1214 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1867 Presidio Ospedaliero G.Jazzolino

location_facility: 9.159.2519 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1100 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2027 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1361 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1825 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1182 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1095 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2704 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2287 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2092 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1187 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1592 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2251 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1639 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1383 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1137 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1110 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2520 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2246 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1171 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2303 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2288 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1035 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1141 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1178 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2250 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1163 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1136 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2963 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2452 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2967 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2177 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2969 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2223 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1098 Community Healthcare Clinic Westhill Medical Specialists

location_facility: 9.159.1169 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1183 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1547 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2513 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2940 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1359 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1737 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2629 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1150 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1679 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1003 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2444 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2057 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1635 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2306 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1342 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1079 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1172 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1070 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2518 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1192 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2244 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1209 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2611 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1215 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2175 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2517 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1213 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1152 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1155 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2504 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1735 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2448 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1159 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1154 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1016 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2503 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1051 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1196 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1631 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2491 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1014 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2107 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1726 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1066 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1712 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2937 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1153 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1220 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1094 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1722 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1544 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2706 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1065 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1515 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2622 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1089 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2483 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1367 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1204 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1637 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2500 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1130 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2283 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1048 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2118 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1553 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2385 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2947 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1374 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2488 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2510 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2961 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2608 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2939 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1027 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1133 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1595 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1043 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2604 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1019 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1121 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2507 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2603 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2089 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1207 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1197 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2102 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1521 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1176 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2628 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1657 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1362 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2180 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2945 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2248 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1148 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2618 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2959 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1865 Ospedale Regionale "S. Salvatore"

location_facility: 9.159.1189 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1122 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1877 Azienda Ospedaliera Umberto I

location_facility: 9.159.1002 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1719 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1820 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1550 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2085 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2389 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2489 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2934 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1382 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2487 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1713 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2499 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2387 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2252 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2485 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2486 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1064 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2207 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2826 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2058 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1549 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1120 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1013 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1008 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2490 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1357 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2962 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1053 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1146 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1203 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2095 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1632 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1111 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1375 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2099 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2082 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1149 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2093 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2521 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2292 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2869 Complexo Hospitalar Universitario Prof Edgard Santos

location_facility: 9.159.2952 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2298 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1546 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2060 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1199 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1097 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1044 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1548 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2825 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1730 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1636 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2800 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1208 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2086 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2293 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1377 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1826 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1134 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1219 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1364 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1210 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1956 TweeSteden Ziekenhuis Tilburg

location_facility: 9.159.1040 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1852 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1731 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1218 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1356 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1396 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2495 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2114 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1128 St. Luke's Hospital MABSI Research

location_facility: 9.159.2853 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1376 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1387 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2621 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2799 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1380 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1202 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2607 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1593 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2291 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1682 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2492 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2295 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1175 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2307 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1049 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1555 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1864 Azienda Ospedaliera "S. Giovanni Battista"

location_facility: 9.159.2797 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1360 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2445 Boehringer Ingelheim Investigational Site

location_facility: 9.159.1017 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2970 Boehringer Ingelheim Investigational Site

location_facility: 9.159.2302 Boehringer Ingelheim Investigational Site


title: A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks

summary: Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients

lead_sponsor: Boehringer Ingelheim

location_country:
Brazil
Mexico
Spain
Germany
France
Poland
Thailand
Romania
Argentina
Australia
Russian Federation
Bahamas
Canada
United Kingdom
Colombia

location_facility: Hospital do Servidor Público Estadual de São Paulo

location_facility: Universidade Federal da Bahia-Unidade Docente Assistencial d

location_facility: Montreal Chest Institute, McGill University Health Centre

location_facility: I.I. Emilio Ribas - Moléstias Infecciosas

location_facility: Hospital Geral de Nova Iguaçu - Ministério da Saúde

location_facility: Canadian Immunodeficiency Research Collaborative Inc.

location_facility: Ciutat Sanitaria Universitaria de Bellvitge

location_facility: Unidade de Pesquisa Clínica (UPC) - AIDS

location_facility: Boehringer Ingelheim Investigational Site

location_facility: Centro de Referência e Treinamento - DST/AIDS

location_facility: UNIFESP/ Hospital São Paulo- Univers. Federal de São Paulo

location_facility: Matei Bals Institute of Infectious Diseases

location_facility: Montreal General Hospital - McGill University Health Centre

location_facility: Sunnybrook & Woman's College Health Science Centre

location_facility: Instituto de Crianca / Hospital das Clínicas-FMUSP


title: An Observer-blind, Multicenter, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, Versus Topical 2% Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo

summary: The goal of this study is to determine if topical SB-275833 ointment, 1% is as safe and effective as topical sodium fusidate ointment, 2% for the treatment of impetigo in adults and children as young as 9 months of age.

ipd_sharing: Yes

ipd_sharing_description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

lead_sponsor: GlaxoSmithKline

location_country:
South Africa
Peru
India
Costa Rica
Mexico
Netherlands
France
Poland
Germany
Canada


title: Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer

acronym: OPUS

summary: This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor (EGFR)-expressing mCRC.

ReferenceCitation: Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.

name: From the University Hospital, Hamburg-Eppendorf; South West German Comprehensive Cancer, University Hospital Tübingen, Tübingen; Merck Serono, Darmstadt Germany; State Medical Academy, City Clinical Hospital #4, Dnepropetrovsk, Ukraine; Moscow City Oncology Hospital #62, Moscow Area, Russian Federation; Hospital Universitario La Fe, Valencia, Spain; Istituto Europeo di Oncologia, Milan, Italy; Institutul Oncologic “Prof. Dr. Al. Trestioreanu” Bucuresti, Bucharest, Romania; Wilhelminenspital der Stadt...

family: Bokemeyer

full_name: Carsten Bokemeyer

given: Carsten

family: Bondarenko

full_name: Igor Bondarenko

given: Igor

family: Makhson

full_name: Anatoly Makhson

given: Anatoly

family: Hartmann

full_name: Joerg T. Hartmann

given: Joerg T.

family: Aparicio

full_name: Jorge Aparicio

given: Jorge

family: de Braud

full_name: Filippo de Braud

given: Filippo

family: Donea

full_name: Serban Donea

given: Serban

family: Ludwig

full_name: Heinz Ludwig

given: Heinz

family: Schuch

full_name: Gunter Schuch

given: Gunter

family: Stroh

full_name: Christopher Stroh

given: Christopher

family: Loos

full_name: Anja H. Loos

given: Anja H.

family: Zubel

full_name: Angela Zubel

given: Angela

family: Koralewski

full_name: Piotr Koralewski

given: Piotr

journal_name: Journal of Clinical Oncology

oa_host_type: repository

repository_institution: Universita Degli Studi Di Milano - Archivio Istituzionale della Ricerca

publisher: American Society of Clinical Oncology (ASCO)

title: Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

ReferenceCitation: Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011 Jul;22(7):1535-1546. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.

full_name: C. Bokemeyer

given: C.

full_name: I. Bondarenko

given: I.

full_name: J.T. Hartmann

full_name: F. de Braud

full_name: G. Schuch

given: G.

full_name: A. Zubel

given: A.

family: Celik

full_name: I. Celik

family: Schlichting

full_name: M. Schlichting

location_country:
Italy
Austria
Spain
France
Poland
Greece
Israel
Romania
Belgium
Russian Federation
Portugal
Germany
Ukraine


title: A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma

summary: The purpose of this study is to test if Symbicort (budesonide/formoterol) Turbuhaler is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort 'as needed' will be compared with Pulmicort (budesonide) Turbuhaler twice daily plus terbutaline Turbuhaler 'as needed'

study_start_date_type: Actual

ReferenceCitation: FitzGerald JM, O'Byrne PM, Bateman ED, Barnes PJ, Zheng J, Ivanov S, Lamarca R, Larsdotter U, Emerath U, Jansen G, Puu M, Alagappan VKT, Surmont F, Reddel HK. Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies. Drug Saf. 2021 Apr;44(4):467-478. doi: 10.1007/s40264-020-01041-z. Epub 2021 Feb 6.

family: FitzGerald

full_name: J. Mark FitzGerald

given: J. Mark

family: O’Byrne

full_name: Paul M. O’Byrne

given: Paul M.

family: Bateman

full_name: Eric D. Bateman

given: Eric D.

family: Barnes

full_name: Peter J. Barnes

given: Peter J.

family: Zheng

full_name: Jinping Zheng

given: Jinping

family: Ivanov

full_name: Stefan Ivanov

given: Stefan

family: Lamarca

full_name: Rosa Lamarca

given: Rosa

family: Larsdotter

full_name: Ulrika Larsdotter

given: Ulrika

family: Emerath

full_name: Ulrika Emerath

family: Jansen

full_name: Gerreke Jansen

given: Gerreke

family: Puu

full_name: Margareta Puu

given: Margareta

family: Alagappan

full_name: Vijay K. T. Alagappan

given: Vijay K. T.

family: Surmont

full_name: Filip Surmont

given: Filip

family: Reddel

full_name: Helen K. Reddel

given: Helen K.

journal_name: Drug Safety

evidence: open (via crossref license)

license: cc-by-nc

license_normalized: cc-by-nc

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

ReferenceCitation: Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1877-1887. doi: 10.1056/NEJMoa1715275.

name: From the Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa (E.D.B.); Woolcock Institute of Medical Research, University of Sydney, Sydney (H.K.R.); Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON (P.M.O.), and the Institute for Heart and Lung Health, University of British Columbia, Vancouver (J.M.F.) — both in Canada; Airway Disease...

title: As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma

ReferenceCitation: O'Byrne PM, FitzGerald JM, Zhong N, Bateman E, Barnes PJ, Keen C, Almqvist G, Pemberton K, Jorup C, Ivanov S, Reddel HK. The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given 'as needed' in mild asthma: study protocols for two randomised controlled trials. Trials. 2017 Jan 10;18(1):12. doi: 10.1186/s13063-016-1731-4.

repository_institution: University of Cape Town - Open University of Cape Town

repositories:
PubMed Central
circle.library.ubc.ca
localhost

title: The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials

ReferenceCitation: Reddel HK, Busse WW, Pedersen S, Tan WC, Chen YZ, Jorup C, Lythgoe D, O'Byrne PM. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet. 2017 Jan 14;389(10065):157-166. doi: 10.1016/S0140-6736(16)31399-X. Epub 2016 Nov 30.

location_country:
Peru
Romania
Australia
Russian Federation
Ukraine
France
Poland
Thailand
Slovakia
Korea, Republic of
Colombia
South Africa
Chile
Sweden
Saudi Arabia
Vietnam
Philippines
Bulgaria
Hungary
Germany
Brazil
Mexico
Czechia
New Zealand
Spain


title: A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF Versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B

summary: The primary objectives of this study are to compare the efficacy, safety, and tolerability of tenofovir disoproxil fumarate (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B. Participants will receive TDF or ADV for 48 weeks (double-blind). After 48 weeks, eligible participants switched to open-label TDF for up to 480 weeks.

ReferenceCitation: Kitrinos KM, Corsa A, Liu Y, Flaherty J, Snow-Lampart A, Marcellin P, Borroto-Esoda K, Miller MD. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014 Feb;59(2):434-42.

ReferenceCitation: Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Aguilar Schall R, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013 Feb 9;381(9865):468-75. doi: 10.1016/S0140-6736(12)61425-1. Epub 2012 Dec 10.

family: Marcellin

full_name: Patrick Marcellin

given: Patrick

family: Gane

full_name: Edward Gane

given: Edward

family: Buti

full_name: Maria Buti

given: Maria

family: Afdhal

full_name: Nezam Afdhal

given: Nezam

family: Sievert

full_name: William Sievert

given: William

family: Jacobson

full_name: Ira M Jacobson

given: Ira M

family: Washington

full_name: Mary Kay Washington

given: Mary Kay

family: Germanidis

full_name: George Germanidis

given: George

family: Flaherty

full_name: John F Flaherty

given: John F

family: Schall

full_name: Raul Aguilar Schall

given: Raul Aguilar

family: Bornstein

full_name: Jeffrey D Bornstein

given: Jeffrey D

family: Kitrinos

full_name: Kathryn M Kitrinos

given: Kathryn M

family: Subramanian

full_name: G Mani Subramanian

given: G Mani

family: McHutchison

full_name: John G McHutchison

given: John G

family: Heathcote

full_name: E Jenny Heathcote

given: E Jenny

journal_name: The Lancet

ReferenceCitation: Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, Martins EB, Yee LJ, Flaherty JF, Kitrinos KM, Rustgi VK, Marcellin P. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013 Aug;58(2):505-13. doi: 10.1002/hep.26277. Epub 2013 May 3.

family: Gordon

full_name: Stuart C. Gordon

given: Stuart C.

name: University HospitalSt. Ivan RilskySofiaBulgaria

family: Krastev

full_name: Zahary Krastev

given: Zahary

family: Horban

full_name: Andrzej Horban

given: Andrzej

name: Liver Unit Asklepios Klinik St. GeorgHamburgGermany

family: Petersen

full_name: Jörg Petersen

given: Jörg

name: Institute for Clinical and Experimental MedicinePragueCzech Republic

family: Sperl

full_name: Jan Sperl

given: Jan

name: Hôpital BeaujonUniversity of ParisClichyFrance

ReferenceCitation: Tsai NC, Marcellin P, Buti M, Washington MK, Lee SS, Chan S, Trinh H, Flaherty JF, Kitrinos KM, Dinh P, Charuworn P, Subramanian GM, Gane E. Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci. 2015 Jan;60(1):260-8. doi: 10.1007/s10620-014-3336-7. Epub 2014 Sep 2.

title: Viral Suppression and Cirrhosis Regression with Tenofovir Disoproxil Fumarate in Asians with Chronic Hepatitis B

ReferenceCitation: Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P, Martins EB, Flaherty JF, Kitrinos KM, Dusheiko G, Trinh H, Flisiak R, Rustgi VK, Buti M, Marcellin P. Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver Int. 2015 Feb;35(2):422-8. doi: 10.1111/liv.12694. Epub 2014 Oct 28.

name: Henry Ford Health System; Detroit MI USA

name: University Hospital; St. Ivan Rilsky Sofia Bulgaria

name: Warsaw Medical University; Warsaw Poland

name: Liver Unit Asklepios Klinik St. Georg; Hamburg Germany

name: Institute for Clinical and Experimental Medicine; Prague Czech Republic

name: Auckland City Hospital; Aukland New Zealand

name: Weill Cornell Medical College; New York NY USA

name: Gilead Sciences Inc.; Foster City CA USA

name: San Jose Gastroenterology; San Jose CA USA

name: Medical University of Bialystok; Bialystok Poland

name: Metropolitan Liver Diseases; Fairfax VA USA

name: Hospital General Universitari Vall d'Hebron and Ciberehd del Instituto Carlos III; Barcelona Catalonia Spain

name: Hôpital Beaujon; University of Paris; Clichy France

ReferenceCitation: Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014 Dec;61(6):1228-37. doi: 10.1016/j.jhep.2014.07.019. Epub 2014 Jul 18.

ReferenceCitation: Buti M, Fung S, Gane E, Afdhal NH, Flisiak R, Gurel S, Flaherty JF, Martins EB, Yee LJ, Dinh P, Bornstein JD, Mani Subramanian G, Janssen HL, George J, Marcellin P. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int. 2015 Apr;9(2):243-50. doi: 10.1007/s12072-015-9614-4. Epub 2015 Mar 13.

ReferenceCitation: Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015 May;60(5):1457-64. doi: 10.1007/s10620-014-3486-7. Epub 2014 Dec 23.

title: Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection

ReferenceCitation: Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017 Jan;24(1):68-74. doi: 10.1111/jvh.12613. Epub 2016 Sep 23.

name: Gilead Sciences, Inc; Foster City CA USA

name: Hospital General Universitari Vall d'Hebron; Barcelona Spain

name: Hôpital Beaujon; University Paris-Diderot; Clichy France

name: Auckland City Hospital; Auckland New Zealand

title: No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg− patients with chronic hepatitis B after 8 years of treatment

ReferenceCitation: Corsa A, Liu Y, Flaherty JF, Marcellin P, Miller M, Kitrinos KM. No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg+ and HBeAg- Patients With Chronic Hepatitis B (CHB) After Eight Years of Treatment [Abstract 1707]. The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD); 2014 08-10 November; Boston MA.

ReferenceCitation: Marcellin P, Gane EJ, Flisiak R, Trinh HN, Petersen J, Gurel S, et al. Long Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection is Safe and Well Tolerated and Associated with Durable Virologic Response with no Detectable Resistance: 8 Year Results from Two Phase 3 Trials [Abstract]. 55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); 2014 November 7-11; Boston, MA.

ReferenceCitation: Gane EJ, Marcellin P, Sievert W, Trinh HN, Shiffman ML, Washington MK, et al. Five years of Treatment with Tenofovir DF for Chronic Hepatitis B Infection in Asian Patients is Associated with Sustained Viral Suppression and Significant Regression of Histological Fibrosis and Cirrhosis [Poster Number 1429]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 2011 November 4-8; San Francisco, California.

ReferenceCitation: Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019 Oct;39(10):1868-1875. doi: 10.1111/liv.14155. Epub 2019 Jul 10.

name: Viral Hepatitis Research Unit Hôpital Beaujon Clichy France

name: Toronto Centre for Liver Disease University Health Network, University of Toronto Toronto Ontario Canada

name: Gastroenterology and Hepatology Unit Monash Health and Monash University Melbourne Australia

name: Liver Unit, IFI‐Institute for Interdisciplinary Medicine Asklepios Klinik St Georg Hamburg Germany

name: Department of Infectious Diseases and Hepatology Medical University Bialystok Bialystok Poland

name: Department of Gastroenterology, Hepatology, and Endocrinology Hannover Medical School Hannover Germany

name: Helmholtz Center for Infection Research (HZI) Hannover Germany

name: Viral Hepatitis Investigative Unit University of Manitoba Winnipeg Canada

name: Clinic of Gastroenterology St Ivan Rilsky University Hospital, Medical University Sofia Bulgaria

name: Liver Unit University of Calgary Calgary Alberta Canada

name: Gilead Sciences Inc Foster City California

name: Liver Unit Hospital Universitario Vall d’Hebron and CIBEREHD del Instituto Carlos III Barcelona Spain

repository_institution: Helmholtz-Zentrum für Infektionsforschung GmbH - HZI Open Repository

title: Ten‐year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection

ReferenceCitation: Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

journal_name: The Lancet Gastroenterology & Hepatology

ReferenceCitation: Jacobson IM, Washington MK, Buti M, Thompson A, Afdhal N, Flisiak R, Akarca US, Tchernev KG, Flaherty JF, Aguilar Schall R, Myers RP, Subramanian GM, McHutchison JG, Younossi Z, Marcellin P, Patel K. Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1087-1094.e2. doi: 10.1016/j.cgh.2017.01.032. Epub 2017 Feb 12.

ReferenceCitation: Bayliss J, Yuen L, Rosenberg G, Wong D, Littlejohn M, Jackson K, Gaggar A, Kitrinos KM, Subramanian GM, Marcellin P, Buti M, Janssen HLA, Gane E, Sozzi V, Colledge D, Hammond R, Edwards R, Locarnini S, Thompson A, Revill PA. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 2017 Nov;66(11):2013-2023. doi: 10.1136/gutjnl-2015-309300. Epub 2016 Aug 17.

ReferenceCitation: Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol. 2015 May 14;21(18):5524-31. doi: 10.3748/wjg.v21.i18.5524.

ReferenceCitation: Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011 Jan;140(1):132-43. doi: 10.1053/j.gastro.2010.10.011. Epub 2010 Oct 16.

title: Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

ReferenceCitation: Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

title: Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B

location_country:
Italy
United States
United Kingdom
Netherlands
Germany
France
Bulgaria
Greece
Poland
Australia
New Zealand
Spain
Turkey
Canada
Czech Republic